Spontaneous B cell lymphoma in dogs: state-of-the-art immunophenotyping and proof-of-concept on immunotherapeutic targets to benefit canine patients

The number of non-chemoresponsive B cell lymphoma (BCL) canine patients is increasing. Through immunophenotyping of lymph nodes and blood, novel markers will be identified that can improve the diagnosis and prognosis of BCL. The potential of these markers as target for neoantigen immunotherapy will be evaluated via the synthesis of nanobodies, whose efficacy will be investigated in a 3D BCL-model.